AstraZeneca has revised the efficacy rate for its US Covid-19 vaccine trial down to 76 per cent as the pharmaceutical group sought to address concerns that it had published incomplete interim data earlier this week.
阿斯利康(AstraZeneca)將其美國新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒?。┮呙缗R床試驗的有效率向下修正為76%。該制藥集團尋求化解本周早些時候出現的、認為其發表了不完整的中期數據的擔憂。
您已閱讀9%（322字），剩余91%（3094字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。